Researchers from the University of Notre Dame have published the first known detailed study of breast cancer tissue from Native American women. The study, published in npj Precision Oncology, reveals important molecular differences that may impact the efficacy of therapies for female, Native American breast cancer patients.

A study by IRB Barcelona and Centro de Investigación del Cáncer in Salamanca demonstrates that eliminating mutated KRAS protein using PROTACs induces rapid tumour regression in mouse models of lung adenocarcinoma.

The work identifies resistance mechanisms distinct from those observed with classic KRAS inhibitors, a relevant finding as the first KRAS degraders are already in clinical trials.

Published in Cancer Research, the developed model could help evaluate future targeted protein degradation-based therapies against other oncoproteins.

Researchers from UC San Diego have uncovered a new possibility for treating melanoma, and it's something we have in our bodies already.

Cancer scientists have discovered that lung cancer cells can change their identity to resist treatment.

With colorectal cancer a growing concern among younger people, the American Cancer Society has endorsed two new types of stool tests to encourage people to get screened while also recommending a limited role for new blood tests many patients find appealing.

The American Cancer Society (ACS) today released updated guidelines for colorectal cancer screening. The new recommendations reaffirm that average-risk adults should begin colorectal cancer screening at age 45 and continue through age 75 for those with a life expectancy greater than 10 years. However, ACS is now adding guidelines for a blood-based screening test taken in a doctor’s office, as well as one updated and one new at-home screening option that looks for hidden blood and molecular markers in stool samples. The move reflects advances in disease detection and a critical shift in public health strategy to expand screening options and lower barriers to access. The update is published in a report in CA: A Cancer Journal for Clinicians, the flagship journal of ACS.

Artificial intelligence is rapidly changing how biomedical materials are discovered and designed. In a new review published in Science Bulletin, researchers summarize how machine learning and generative AI are helping scientists predict material behaviors such as drug release, biocompatibility, and catalytic activity, and even propose entirely new inorganic materials for biomedical applications. The review highlights emerging applications in drug delivery, cancer therapy, anti-inflammatory treatment, and tissue engineering, while also discussing the challenges that still limit clinical translation.

Androgen receptor (AR) signaling plays a critical role in prostate cancer progression and remains a primary therapeutic target. Despite the efficacy of androgen deprivation therapy (ADT), most patients eventually develop castration-resistant prostate cancer (CRPC), characterized by the reactivation of AR signaling through various mechanisms. While the role of AR as a transcriptional activator is well-documented, emerging research indicates that it also functions as a transrepressor for specific targets.